Camoteskimab

DB18876InvestigationalProtein Based Therapies

Camoteskimab is under investigation in clinical trial NCT06436183 (A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis).

Mechanism: Pharmacologically active on Interleukin-18
Curator reviewed
Also known as: Immunoglobulin g1 (242-phenylalanine,243-glutamic acid,339-serine), anti-(human interleukin 18) (human monoclonal cerc-007 .gamma.1-chain), disulfide with human monoclonal cerc-007 .kappa.-chain, dimer
Code names: AEVI-007 · CERC-007 · MEDI-2338

Resolves to

Compound

UNIIONX021SC9OCAS2492472-82-7

Targets

Q14116IL18

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Camoteskimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account